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We appreciate the comments of Drs. Robbins, Barst, Channick
and Rubin. They are pioneers within the field of pulmonary
hypertension, and their studies and reviews have laid the ground-
work for present and future research. However, we would like to
reiterate our published response rates to inhaled nitric oxide (NO)
in primary pulmonary hypertension (PPH) and pulmonary hyper-
tension from secondary causes (SPH). We agree that the definition
of a positive response to vasodilators is not uniform throughout the
literature, and for this reason we included a table in our publication
examining our results using different definitions (1). This allows
the reader to compare our results with those of our colleagues at
different institutions.
Although Robbins and colleagues correctly state that most
previous studies of vasodilators in PPH have response rates lower
than our series, other series, particularly Atz et al. (2), have shown
up to an 88% positive response rate to vasodilators. Why should
such a wide discrepancy exist between studies? We agree that this
is very disconcerting at first glance. But even within the Robbins et
al. series of three institutions, a nearly threefold difference in
response was seen between the investigators at the University of
California at San Diego (UCSD) and the investigators at Colum-
bia University. Should a twofold difference between the investiga-
tors at Columbia and our group be so surprising? A more thorough
description of baseline hemodynamics in each patient group may
help explain the difference in response rates. The majority of
patients in our study were undergoing initial right heart catheter-
ization for assessment of vasoreactivity. This would imply an
earlier stage of disease, when the abnormalities at the vascular level
may still be reversible. The higher response rates in children (3)
may imply a difference in the pathophysiology of PPH in children,
but it is more likely a result of earlier diagnosis and testing in this
population. A young, active individual may notice a subtle limitation
in physical endurance earlier and be brought to medical attention.
In our study, right ventricular dysfunction was more common in
patients unresponsive to vasodilators. This was likely a result of
more advanced disease. To date, no patient we have tested
experienced a $20 mm Hg drop in pulmonary artery pressure if
their baseline right ventricular end-diastolic pressure was
.20 mm Hg. We have recently reviewed the echocardiograms of
these patients and found that right ventricular (RV) systolic
dysfunction correlates strongly with vasodilator response. In our
population, significant RV dysfunction was rare (,20%), implying
a fairly healthy population.
Present-day determination of vasoreactivity should occur in a
cardiac catheterization laboratory with careful attention to hemo-
dynamic measurements. We have not observed any hemodynamic
instability during testing, and we have not found it necessary to
repeat baseline measurements between escalating doses of NO.
In conclusion, we have presented the results of vasodilator
testing at Duke University Medical Center for the express purpose
of comparing response rates of SPH patients with those of PPH
patients. We have observed similar degrees of vasoreactivity in
both groups, and we have proposed that further studies be
conducted. We also stated that assessment of vasoreactivity would
be an essential first step in determining whether treatment with
calcium channel blockers would be feasible and safe in these
patients. We agree with Robbins and colleagues that empiric
treatment of patients with SPH or PPH without safety data is
dangerous in these patients, particularly if RV dysfunction is already
present. Larger studies will be useful in sorting out the variability in
response rates documented at different centers.
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Coronary Artery Revascularization in Patients
With Sustained Ventricular Arrhythmias in
the Chronic Phase of a Myocardial Infarction
Although Brugada et al. (1) are to be commended for their efforts
to clarify the complex relationship between postinfarction sus-
tained ventricular arrhythmias and coronary revascularization, their
study is limited by important methodologic flaws and questionable
inferences. First, only crude unadjusted estimates of effects were
reported. Therefore, the analysis failed to control for numerous
potential confounding variables such as age, gender, ejection
fraction, type of revascularization, number of diseased vessels and
medical therapy. Second, analysis of cohort data must fundamen-
tally account for unequal lengths of time that participants are
observed for the outcome of interest (e.g., number of recurrent
ventricular arrhythmias per unit time per person) (2). Whereas the
Kaplan-Meier product-limit estimate may be a useful statistical
tool to assess event-free survival in a given population, comparing
uncontrolled subgroups is highly disputable. Moreover, unstable
estimates result when the number of events (Ak) at each time (Tk)
is a large portion of the number at risk at that time (Nk) (i.e.,
Ak/Nk must be small) (3). This condition is violated in both
analyses reported in Figures 1 and 2 (1). A multivariate predictive
model that accounts for length of follow-up and adjusts for
covariates (e.g., Cox proportional hazards survival model or Pois-
son regression) would have been a more appropriate and mean-
ingful method of analysis. Furthermore, most reported p values are
derived from markedly underpowered comparisons and may there-
fore be deceiving. For example, to detect a 15% difference at 80
months (see Fig. 2) in recurrent events in noninducible (n 5 10)
compared to inducible patients (n 5 52), only a power of 13.6% is
obtained (given a standard two-tailed a 5 0.05).
Perhaps most questionable is the unsubstantiated inference that
their results suggest “that the combination of coronary artery
revascularization and antiarrhythmic therapy (drug therapy or
defibrillator implantation) is an excellent combination and should
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be used systematically.” Conclusions regarding the value of revas-
cularization can clearly not be deduced from a study of only
revascularized patients, especially if one considers the high re-
ported rate of recurrent ventricular arrhythmias despite routine
revascularization (i.e., 32/62 5 58%). Great caution must be
exerted in interpreting the reported data to avoid unfounded
conclusions and their important implications.
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REPLY
We appreciate Dr. Khairy’s interest in our article recently pub-
lished in the Journal of the American College of Cardiology.
Dr. Khairy argues that some methodologic aspects of the work
are questionable. The objective of our study was not to investigate
independent factors predictive of recurrent events during follow-
up, but rather to compare several variables between those having or
not having recurrent events. In that case, and owing to the limited
number of patients, a univariate analysis seems correct.
Our report is an observational study in a very specific patient
population with limited information on the literature so far. We
never intended to investigate the value of revascularization or
antiarrhythmic therapy in such a population. The objective was to
report that the combined approach gives excellent results in terms
of survival (compared to historical series), and that revasculariza-
tion alone does not prevent arrhythmic recurrences.
The conclusion that an individualized combined approach gives
excellent results and should be used systematically seems reason-
able. In patients with a clear indication for revascularization and
who have suffered clinically sustained ventricular arrhythmias, a
randomized study using different combinations of revascularization
yes or no and antiarrhythmic therapy yes or no would probably be
methodologically correct but certainly ethically incorrect.
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Management of Anomalous Coronary Artery
The Davis et al. (1) finding of a 0.17% prevalence of anomalous
coronary artery from the wrong aortic sinus in an asymptomatic
pediatric population is important data. These investigators and
others (2) suggest that surgical management is mandatory, while
admitting that the duration of coronary artery bypass graft surgery
(CABG) patency is not known. The accompanying editorial is
more cautious for asymptomatic patients ,35 years of age, citing
uncertainty surrounding the most appropriate management option
and stating that “surgical repair should be considered” (3). Pelliccia
(3) also believes that these lesions in patients .35 years of age have
“likely no clinical significance” and “most probably [need] no
surgical treatment.”
I am concerned that the specter of sudden death seems to have
compelled many to “do something,” in the absence of good
outcomes data. A prevalence of ;0.1% to 0.2% among ;4 million
live births annually in the U.S. (4) yields about 4,000 to 8,000
children born each year with these coronary anomalies. Of 275
million people in the U.S. (assuming a low incidence of death),
;275,000 to 550,000 would be affected; approximately half are
under age 35. (As an aside, the risk in an adult over age 35 may not
be insignificant, as a recent case report shows [5].) And yet, the
number of cases of sudden death appears exceedingly small when
compared with these population figures (,,1%), as data from U.S.
and Italian registries suggest (2). Is this truly the natural history of
these lesions, or are we underestimating the risk?
The CABG procedure is not risk-free (6,7). Admittedly, surgi-
cal risk is likely to be lower in patients with anomalous coronary
artery from the wrong sinus than with other coronary problems, as
patients are typically healthy. Nevertheless, even the simplest of
pediatric heart operations carry risks of neurologic, myocardial, and
other organ injury, as well as death. Moreover, surgical “repair” by
no means guarantees cure. One recent study of children showed
patency rates of 78% and 36% for internal mammary grafts and
saphenous vein grafts, respectively, at 10 years (7). Such figures
virtually guarantee reoperation in most patients, with its concom-
itant risks.
Some physicians and families may prefer to accept the surgical
risks rather than to live with an unknown potential for sudden
death, but these risks must be fully understood before an operation
is undertaken. I do believe that activity can often be modified, and
therefore risk can be reduced, even if not eliminated. But the
unanswered questions remain: 1) What is the true natural history
of these coronary anomalies? 2) What is the long-term “unnatural
history” of CABG in children? Although sudden death, particu-
larly in a young and seemingly healthy person, is especially tragic,
we must remember the fundamental principle of primum non
nocere—“first, do no harm.” Therefore, when it comes to surgical
management, one must consider the adage, however difficult:
“Don’t just do something, stand there!”
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